Is There a New Treatment for Alzheimer’s and Dementia? Stem Cell Therapy in Japan

Is there a new treatment for Alzheimer’s?

Yes — on two fronts. The first is a new class of approved drugs (Leqembi/lecanemab and donanemab) that clear amyloid and modestly slow decline. The second is regenerative medicine, where stem cell therapy for Alzheimer’s is emerging as a different approach aimed at inflammation, not just amyloid.

For years, the honest answer to “is there a cure for Alzheimer’s?” was no — only symptom drugs. That has started to change. But each option comes with trade-offs, and no treatment yet reverses the disease.

This guide lays out both paths plainly: what the new drugs achieve and where they fall short, what stem cells may add, who each suits, and why some families weigh a regenerative option — as a complement, or when the drugs are not a fit.

How the new Alzheimer’s drugs work — and why some people look further

Leqembi (lecanemab) and donanemab are the first approved drugs that change the disease rather than just symptoms, by removing amyloid from the brain. In its pivotal trial, lecanemab slowed decline on one scale by about 27% at 18 months — real progress, but not a stop or reversal.

The catch is tolerability. As summarized in the 2025 phase 2a report in Nature Medicine, lecanemab carried a 21.5% rate of amyloid-related imaging abnormalities (ARIA — brain swelling or small bleeds) and a 26.4% rate of infusion reactions, while donanemab carried a 36.8% ARIA rate. For some patients these risks, or eligibility limits, make the drugs a difficult fit.

This is where a second option enters. For people anxious about ARIA, ineligible for anti-amyloid drugs, or simply wanting to reinforce their care, stem cell therapy offers a different mechanism — one with no ARIA reported in trials. To be clear: the approved drugs remain the first-line, evidence-based step, and stem cell therapy is best framed as a complement or alternative to discuss with a physician, not a replacement.

Why stem cells for Alzheimer’s and dementia — the story beyond amyloid

Because Alzheimer’s is not only about amyloid. A growing body of research points to neuroinflammation — chronic inflammation inside the brain — and failing small blood vessels as major drivers of neuronal death, alongside amyloid and tau. Anti-amyloid drugs address one piece; stem cells aim at another.

The Nature Medicine trial states it directly: non-amyloid contributions to Alzheimer’s include “cerebrovascular degradation and a neuroinflammatory component contributing to neuronal death and brain atrophy.” Calming that inflammation may protect the brain in ways amyloid removal alone does not.

This is the area Cell Grand Clinic’s director, Dr. Yuichi Wakabayashi, built his research on. As first author at the US National Institutes of Health, he developed PET imaging tracers for the brain enzyme PDE4B — a regulator of inflammatory (cAMP) signaling implicated in dementia — published in the Journal of Nuclear Medicine. His related work on PDE4D, in ACS Chemical Neuroscience, mapped this enzyme to memory regions such as the hippocampus.

So why stem cells? Mesenchymal stem cells (MSCs — repair cells found in fat, marrow, and cord tissue) act largely through anti-inflammatory and immune-modulating signals. They also support blood vessels and release paracrine (“messenger”) factors that aid surrounding tissue. That biology fits the inflammatory view of dementia — which is why researchers are testing it.

What the science shows (and what it doesn’t)

Early results are encouraging but small. In the strongest study to date, intravenous stem cell therapy slowed brain-volume loss by 48.4% versus placebo, with no ARIA — a promising signal for a new dementia treatment, though not proof it reverses Alzheimer’s.

In plain terms: in a 2025 phase 2a study in Nature Medicine, people with mild Alzheimer’s on monthly infusions held on to more brain volume than those on placebo, and hippocampal shrinkage tracked with memory scores. That trial used donor (allogeneic) cells; Cell Grand Clinic uses your own adipose cells, so the biology overlaps but the product differs.

Supporting this, a phase I/II trial of adipose-cell exosomes in General Psychiatry reported no adverse events, and a 2024 systematic review in Dementia & Neuropsychologia examined the safety and efficacy of cell-based therapies in Alzheimer’s. We would rather be candid than oversell: the human efficacy data are still early and small, so no one can promise outcomes.

Is stem cell therapy safe — and how does ARIA compare?

For the delivery method, the safety record is reassuring, and — unlike anti-amyloid drugs — no ARIA has been reported. Intravenous MSC infusion has shown no meaningful rise in serious side effects across many conditions; when side effects occur, they are usually mild and temporary, such as short-lived fatigue or headache.

The clearest data come from other diseases tested at scale. A meta-analysis of 13 randomized trials and 655 patients with acute respiratory distress found no significant difference in adverse events between IV MSC and control (odds ratio 0.64, 95% CI 0.34–1.20), in Critical Care. In the Alzheimer’s trials, serious adverse events stayed low (roughly 0–9%) with no ARIA.

That said, “generally safe” is not “risk-free.” Because Cell Grand Clinic uses autologous cells (your own, not a donor’s), the risk of immune rejection is low. Still, every procedure carries some risk, outcomes vary by individual, and any decision should be made with a qualified physician.

Who is it for — and who is it not for?

It suits people diagnosed at an early-to-middle stage of Alzheimer’s or other dementias, and, earlier still, those acting preventively or with a family history. As with most conditions, earlier treatment carries the higher chance of benefit. For advanced-stage dementia patients, there is little data and meaningful benefit is unlikely — so it is generally not recommended there.

Frontotemporal and other subtypes are assessed case by case. Because this is a biological process rather than a single fix, more than one session is usually needed, and any benefit tends to build gradually — which is why it fits a longer-term brain-health plan.

Why Japan — and why Cell Grand Clinic

Because Japan regulates this treatment under a formal legal framework, and because your own cells carry no donor-rejection risk. Most overseas stem cell therapy for dementia — in Mexico, Panama, the Cayman Islands, or Thailand — relies on donor cells with lighter oversight; Cell Grand Clinic’s model is deliberately different.

Cell Grand Clinic operates under Japan’s MHLW Type 2 certification, a higher-tier risk classification within the Act on the Safety of Regenerative Medicine for treatments using cultured autologous cells. Treatment uses adipose-derived stem cells grown from your own fat over seven weeks — never donor cells — delivered and followed by the physician directly. For Alzheimer’s disease specifically, the clinic’s Type 2 provision plan — “Treatment of Alzheimer’s disease with autologous adipose-derived stem cells” (Plan No. PB5260030) — has been formally accepted and is listed in the MHLW public database of regenerative medicine provision plans. Dr. Wakabayashi has performed 3,000+ treatments for patients from around 20 countries.

Quality is standardized under Cell Grand Clinic’s Grand Stem Cells program, built on four commitments:

• Cultured exclusively for you — no stock or off-the-shelf product; every batch is grown from your tissue after treatment is decided.
• ISCT-standard verification — surface-marker testing confirms the cells are genuine mesenchymal stem cells; anything below standard is discarded.
• 95%+ viability — only living cells — viability is checked right up to infusion, because dead cells do not help tissue.
• Youth and volume, without compromise — cells are held to passage 3 or below and grown to as many as 200 million, keeping them young and active.

Every patient receives a Certificate of Quality documenting that their Grand Stem Cells met all four standards. Cell Grand Clinic frames this therapy as a complement to — not a replacement for — the medication, cognitive care, and lifestyle steps that remain the foundation of dementia treatment.

The pathway at Cell Grand Clinic is straightforward:

1. Inquiry and review — you share history and current treatments; Dr. Wakabayashi reviews the case.
2. Assessment and fat sampling — a small fat sample is taken for your personal cell line.
3. Seven-week culture — your cells are grown to target number and quality.
4. Care during culture — exosome or PRP support can be given the same day, so the weeks are not idle.
5. Infusion — your own cells are delivered by IV.
6. Follow-up — remote review at 1, 3, and 6 months.
Stem cell therapy in Japan: cost, safety & what the research shows →
Learn more

Frequently asked questions

Is there a cure for Alzheimer’s?

Not yet — no therapy fully reverses Alzheimer’s. But real options have arrived: anti-amyloid drugs can slow decline, and stem cell therapy is an emerging regenerative treatment that aims to protect brain function. Results vary by individual, and earlier treatment gives the better chance.

Is stem cell therapy better than lecanemab (Leqembi)?

They are different, not ranked. Lecanemab is an approved drug that clears amyloid but carries ARIA risk. Stem cell therapy is an emerging option targeting inflammation, with no ARIA reported. Many patients discuss using them together, under medical guidance.

How much does stem cell therapy for dementia cost?

At Cell Grand Clinic, pricing starts from $19,800 USD per session, including 100 million autologous cells, seven-week culture, a quality certificate, and follow-up. Final cost depends on cell count, combination protocols, and sessions, so it varies by case.

Is stem cell therapy for Alzheimer’s available in Japan?

Yes. Cell Grand Clinic in Osaka provides autologous adipose-derived stem cell therapy under Japan’s MHLW Type 2 certification, with English-speaking, physician-led care for overseas patients.

How many sessions are needed?

Usually more than one. Because the effect is biological and gradual, repeated infusions are common, mirroring the monthly dosing used in clinical trials. Dr. Wakabayashi recommends a number based on your stage and goals.

Does stem cell therapy help other types of dementia (vascular, Lewy body, frontotemporal)?

Alzheimer’s disease has the most clinical-trial data so far, but the mechanism — calming neuroinflammation and supporting small blood vessels — is being studied across other dementias, including vascular and mixed types. Frontotemporal, Lewy body and other subtypes are assessed case by case, and advanced-stage disease of any type is generally not suitable. Dr. Wakabayashi reviews each diagnosis individually before recommending treatment.

References

1. Rash BG, Ramdas KN, Agafonova N, et al. Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial. Nature Medicine. 2025;31(4):1257–1266. https://doi.org/10.1038/s41591-025-03559-0
2. Xie X, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: a phase I/II clinical trial. General Psychiatry. 2023. https://doi.org/10.1136/gpsych-2023-101143
3. A systematic review of clinical efficacy and safety of cell-based therapies in Alzheimer’s disease. Dementia & Neuropsychologia. 2024. https://doi.org/10.1590/1980-5764-DN-2024-0147
4. Wang F, Li Y, Wang B, Li J, Peng Z. The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials. Critical Care. 2023;27(1):31. https://doi.org/10.1186/s13054-022-04287-4
5. Wakabayashi Y, Stenkrona P, Arakawa R, et al. First-in-human evaluation of [18F]PF-06445974, a PET radioligand that preferentially labels phosphodiesterase-4B. Journal of Nuclear Medicine. 2022;63(12):1919–1924. https://doi.org/10.2967/jnumed.122.263838
6. Wakabayashi Y, Telu S, Dick RM, et al. Discovery, radiolabeling, and evaluation of subtype-selective inhibitors for PET imaging of brain phosphodiesterase-4D. ACS Chemical Neuroscience. 2020;11(9):1311–1323. https://doi.org/10.1021/acschemneuro.0c00077

Medically reviewed by Yuichi Wakabayashi, MD, PhD (Diplomate, American Board of Regenerative Medicine; NIH-trained) — Last reviewed: 2026-07-02

Updated: 2026.08.20